You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Interactive technology for media literacy drug prevention in community groups
SBC: REAL PREVENTION LLC Topic: NIDAThe goals of this Phase II STTR are to evaluate the outcomes of REAL mediaan interactiveselfpacede learning substance use prevention media literacy curriculum and prepare it for marketing to community organizationsincluding our partnerHSubstance use increases in frequency and risk through mid adolescenceyet prevention interventions primarily target early useare time intensiveand are implemented in ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Towards a New Generation of Glycoengineered Pneumococcal Bioconjugate Vaccines
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Pneumococcal pneumonia remains the leading cause of bacterial pneumonia in both children under years of age and adults over years of age The standard preventative therapy is the conjugate vaccine Prevnar which consists of an immunogenic carrier protein covalently attached to one of thirteen pneumococcal capsular polysaccharides Although Prevnar has significantly red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Soluble E NTPDase for sepsis
SBC: Purine Pharmaceuticals Inc. Topic: NIGMSSUMMARY Sepsis is a medical condition caused by an overwhelming systemic inflammatory response to infection Although the underlying infection can now be efficiently treated with antibiotics there are no effective therapies to control the organ damage caused by the inflammatory response of the host As a result sepsis is the leading cause of mortality in intensive care units and is the tenth lea ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
ErythroMer Nanoscale Bio Synthetic Red Cell Substitute
SBC: KaloCyte Inc Topic: NHLBIPROJECT SUMMARY There is need for an artificial oxygen O carrier to substitute for banked blood in settings where stored blood is unavailable pre hospital care transport austere environments undeveloped countries or undesirable transfusion risk exceeds benefit To address this need we developed ErythroMer EM a first in class nano cyte blood substitute EM is a deformable ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A practical and versatile high resolution D dosimetry system for clinical use
SBC: HEURIS INC. Topic: 102Quality assurance QA is a critical component of radiation oncology that ensures both effective treatment delivery and patient safety Over the last decade dQA is now particularly important asramatic innovations in treatment delivery technologiesy have led to increasingly sophisticated and complex treatments that are difficult to adequately verify with conventional dosimetric verification system ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Telehealth Intervention for Improved Blood Pressure Control with Targeted Incentives Using New Technologies and Insights From Behavioral Economics to Increase the Effectiveness of Behavioral Change
SBC: Wellth Inc. Topic: NIAPROJECT SUMMARY ABSTRACT Hypertension or sustained systolic and diastolic blood pressure BP of and mm Hg or higher is among the most frequently encountered conditions in primary care in the U S The estimated prevalence is among all U S adults and increases with age to affect of seniors Hypertension is also the leading risk factor for cardiovascular disease global mortality ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Develop a new cisplatin based drug combination with reduced ototoxicity
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY In spite of recent new drug developments platinum based drugs such as cisplatin are still widely used to treat solid organ malignancies Besides its limited efficacy serious side effects have been associated with the use of cisplatin such as bilateral and irreversible hearing loss In the cochlea cisplatin can trigger the production of reactive oxygen species and activate sev ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Small Molecule Therapy for the Treatment of Heart Failure
SBC: SUMOCOR LLC Topic: NHLBIABSTRACT The incidence of heart failure HF continues to increase in the United States despite significant advances in pharmacological therapies and novel devices There is an acute need for novel treatment strategies for heart failure A key abnormality in HF is defective handling of calcium that has been partially related to abnormal sarcoplasmic reticulum SR function in cardiac myocytes Red ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Fibrin Specific Nuclear Probe to Reduce LVAD Adverse Events
SBC: CAPELLA IMAGING, LLC Topic: NHLBIDespite the myriad major advances in cardiology the prognosis for patients with severe medically refractive heart failure HF is exceedingly poor Approximately deaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizations At least of these deaths were directl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health